Spain's Grifols (GRLS.MC) wants to close its $4 billion bid for peer Talecris (TLCR.O) next month, but the deal to create the world's third-largest player in blood-derived products still needs U.S. regulatory approval. Grifols agreed to buy Talecris last year to help boost market share in the United States and Canada and strengthen its position versus rivals such as Baxter International (BAX.N) and Australia's CSL (CSL.AX).[ID:nLDE6560AA] These firms make treatments derived from donated blood plasma used to treat a range of conditions, including haemophilia and immune system deficiencies. The U.S. Federal Trade Commission (FTC) is set to make a decision soon. What are the chances of the FTC approving the deal, and how would different FTC rulings affect Grifols' share price?
Source
